ESHAP方案治疗复发或难治性侵袭性非霍奇金淋巴瘤

 【摘要】　目的　观察ESHAP方案作为解救化疗方案治疗复发或难治性侵袭性非霍奇金淋巴瘤（NHL）的疗效和安全性。方法　选取38例复发或难治性侵袭性NHL患者，使用ESHAP方案（依托泊苷、甲泼尼龙、顺铂、阿糖胞苷）作为解救方案进行化疗。结果　38例患者各接受了2～6个周期ESHAP方案化疗，总的客观有效率为55.3 %，完全缓解率26.3 %；主要不良反应为骨髓抑制伴感染，均可耐受。结论　ESHAP方案是治疗复发或难治性侵袭性NHL安全有效的解救方案之一。

Clinical study of ESHAP regimen for relapsed or refractory aggressive non-Hodgkin lymphoma

【Abstract】　Objective　To evaluate the efficacy and safety of ESHAP regimen, as a salvage regimen, in treating patients with relapsed or refractory aggressive NHL． Methods　38 patients with relapsed or refrac－tory aggressive NHL were selected to be treated by ESHAP regimen． Results　The 38 patients received ES－HAP regimen with a range of 2 ～ 6 cycles. The total RR was 55.3 % with complete response (CR) rate of 26.3 %. The major toxicity was myelosuppression with infection, which was tolerable. Conclusion　ESHAP regimen is one of safe and effective salvage regimens for the patients with relapsed or refractory aggressive NHL．